NOVARTIS N overview

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate PR Newswire BOSTON, Nov. 18, 2024 Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON , Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. ( Ratio ), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and...

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer PR Newswire EAST HANOVER, N.J., Oct. 18, 2024 If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali ® (ribociclib) in combination with an aromatase inhibitor 1 Recommendation is based on the Phase III...

NORTHAMPTON, MA / ACCESSWIRE / August 26, 2024 / Common Impact As seen on commonimpact.org Charlotte Rocker and Dan Barnett might come from different worlds, but they share a common passion for making a difference. Charlotte, a dynamic product strategy lead at Novartis , is passionate about bringing innovative medicines to patients in need. On the other hand, Dan is a dedicated leader in the nonprofit sector, steering Students 2 Science (S2S) as the Chief Development officer to bring STEM...

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) PR Newswire East Hanover, N.J., Aug. 7, 2024 Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001) 1 Fabhalta is an inhibitor of the alternative complement...

Department of Health - Abu Dhabi and Novartis to Partner to Advance Genomics Research in Oncology and Beyond PR Newswire ABU DHABI, UAE, June 7, 2024 ABU DHABI , UAE, June 7, 2024 /PRNewswire/ -- At BIO 2024 International Convention , the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Novartis Middle East FZE , a global pharmaceutical company. Under the terms of the MoU, the entities will work...

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire EAST HANOVER, N.J., May 25, 2024 In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks 1 Endothelin A (ETA) receptor activation contributes to elevated...

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo PR Newswire EAST HANOVER, N.J., May 25, 2024 Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo 1 ; additional 6-month open-label data to be presented at a future medical meeting 2,3 Fabhalta showed a favorable safety profile with no...

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) PR Newswire EAST HANOVER, N.J., April 15, 2024 APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN 1 IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease...